An antiretroviral drug has been developed that could protect uninfected people from HIV. The drug can be taken as an injection every two months making it the closest yet to an HIV-AIDS vaccine.
The large scale study which was partly interrupted by the coronavirus pandemic offers a potential easier alternative to taking daily pills of other antiretrovirals.
The new treatment, Cabotegravir, is 69% more effective than the pill, Truvada and awaits final approvals.
The HIV prevention market is currently worth some $2 billion in the US alone and could potentially double in the next decade.
Read Also: Earth’s Ozone Layer Is Healing – Study
HPTN 083, the name of the Cabotegravir study has 43 sites in the US, Argentina, South Africa, Brazil, Peru, Vietnam and Thailand. The coronavirus pandemic forced 11 of the sites to close while the other struggled to continue because pariticipants increasingly had difficulties making appointments.
Cabotegravir targets an HIV enzyme called integrase that is essential to its replication. The drug is made by ViiV healthcare , a joint venture pf GSK, Pfizer and Shionogi that focuses on anti-HIV drugs.
Culled from: ScienceMag